David Philibert

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

Fernando C. Fervenza, Gerald B. Appel, Sean J. Barbour et al. · New England Journal of Medicine · 2019 · 600 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

Frank B. Cortazar, John L. Niles, David Jayne et al. · Kidney International Reports · 2023 · 85 citations · Full text

Medicine, Internal Medicine, Nephrology +16

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)

Fernando C. Fervenza, Pietro A. Canetta, Sean J. Barbour et al. · ˜The œNephron journals/Nephron journals · 2015 · 69 citations

Medicine, Immunology, Nephrology +15

The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

Vibeke Strand, David Jayne, Audra Horomanski et al. · The Lancet Rheumatology · 2023 · 30 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +15

Incidence and severity of early electrolyte abnormalities following autologous haematopoietic stem cell transplantation

David Philibert, Simon Desmeules, A. Jordan Filion et al. · Nephrology Dialysis Transplantation · 2007 · 19 citations

Medicine, Biomedical Sciences, Hematology +14